Rankings
▼
Calendar
DNLI Q3 2023 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena
DNLI
Denali Therapeutics Inc.
$3B
Q3 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$1M
-64.4% YoY
Gross Profit
$1M
100.0% margin
Operating Income
-$114M
-8981.5% margin
Net Income
-$99M
-7841.6% margin
EPS (Diluted)
$-0.72
QoQ Revenue Growth
-99.6%
Cash Flow
Operating Cash Flow
-$87M
Free Cash Flow
-$89M
Stock-Based Comp.
$27M
Balance Sheet
Total Assets
$1.2B
Total Liabilities
$118M
Stockholders' Equity
$1.1B
Cash & Equivalents
$148M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$1M
$4M
-64.4%
Gross Profit
$1M
$4M
-64.4%
Operating Income
-$114M
-$107M
-5.9%
Net Income
-$99M
-$103M
+3.8%
← FY 2023
All Quarters
Q4 2023 →